Electrochemically activated chemotherapy (EAC) is two things:
 

1. A natural philosophy school of biomimetic pharmaceutical design; and or, 

2. A type of patented medical treatment that uses a chemotherapeutic galvanostat/potentiostat (CGP) to activate prodrugs and or precursor molecules.

EAC is biomimetic and the only technique that uses electrochemistry as a mechanism of prodrug activation. 

EAC is sometimes also referred to as electroactivated chemotherapy, artificial bioactivation, or electrodrugs.

​

EAC can use any type of redox reactive precursor molecule including antibodies, proteins, small molecules, inorganic molecules and ions, and DNA and RNA.

​

Using a CGP, individuals and teams are able to develop and test redox sensitive drugs for further market development, going so far as to design electro-reactive chaperone leaving groups to active molecules, as with the case of cyclophosphamide, a World Health Organization anti-cancer molecule in-use since the 1960s.

​